在阿尔茨海默病中探索大麻素调节对自机制的研究:一篇综述
C Ntsapi1, M Weyers2,3, R Chinheya2,3
1Department of Basic Medical Sciences, School of Biomedical Sciences, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Frontiers in pharmacology
|January 28, 2026
概括
多种大麻素治疗可能会提高阿尔茨海默氏症中神经元的存活率.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及有毒的蛋白质聚合物和受损的自,导致神经退行.
- 来自Cannabis sativa的cannabinoids在微剂量时显示出神经保护作用.
- 多种大麻素治疗对AD模型中自和细胞存活的影响尚不清楚.
研究的目的:
- 探索多种大麻素治疗方法,以提高在阿尔茨海默氏症体外模型中的神经元存活率.
- 调查大麻素在激活自和改善神经元弹性方面的潜力.
- 阐明将大麻素,自和AD中的神经元活力联系在一起的分子机制.
主要方法:
- 审查有关大麻素,自和阿尔茨海默病的现有文献.
- 探索体外阿尔茨海默病模型.
- 分析多种大麻素组合的潜力,以提高自的调节.
主要成果:
- 大麻素在调节自途径方面显示出潜在的潜力.
- 多种大麻素策略可能会增强神经元细胞存活率.
- 内激素系统是阿尔茨海默氏症治疗发展的目标.
结论:
- 多种大麻素治疗为增强阿尔茨海默氏症的自和神经元存活提供了一个有希望的途径.
- 对内分泌系统的进一步研究可能会导致新的AD治疗方法.
- 了解这些机制可以帮助减轻阿尔茨海默病的影响.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
13.1K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
10.1K
相关概念视频
Delivery Pathways to the Lysosome
7.7K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
7.7K
Autophagy
5.1K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.1K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
